Clinical Edge Journal Scan

Syndesmophyte formation is a rare event in PsA


 

Key clinical point: Patients with psoriatic arthritis (PsA), except those with elevated C-reactive protein (CRP) levels (≥10 mg/L) and radiographic sacroiliac involvement, generally had a very low likelihood of developing syndesmophytes.

Major finding: At 2 years of follow-up, the majority (~90%) of patients showed no new syndesmophyte development, with syndesmophyte development being reported in only 11 patients. The probability of developing vs not developing syndesmophytes increased numerically by 3 and 14 times in patients with radiographic sacroiliitis and in those with radiographic sacroiliitis plus elevated CRP levels, respectively.

Study details: Findings are from an analysis of the data of 150 patients with PsA from the Belgian Epidemiological Psoriatic Arthritis Study (BEPAS) trial who had baseline and 2-year follow-up radiographs available.

Disclosures: The BEPAS trial was funded by MSD Belgium. Some authors declared receiving consultancy fees, speaker fees, or research grants from or having other ties with various sources, including MSD.

Source: de Hooge M et al. Specific descriptions of axial involvement are associated with radiographic damage development after 2 years in psoriatic arthritis patients. Ann Rheum Dis. 2023 (Nov 2). doi: 10.1136/ard-2023-224501

Recommended Reading

TNF blockers not associated with poorer pregnancy outcomes
MDedge Rheumatology
Apremilast beats placebo in early PsA affecting few joints
MDedge Rheumatology
Predictors of minimal disease activity achievement in upadacitinib-treated PsA
MDedge Rheumatology
Real-world study shows favorable efficacy-safety profile of dual targeted therapy in refractory PsA
MDedge Rheumatology
Ixekizumab improves disease signs and symptoms in patients with severe PsA
MDedge Rheumatology
Tildrakizumab may check the progression to PsA in psoriatic patients
MDedge Rheumatology
Cathepsin K and G levels in serum and synovial fluid hold diagnostic potential in PsA
MDedge Rheumatology
PsA tied to increased risk of depressive symptoms and functional impairment
MDedge Rheumatology
Meta-analysis identifies the biologic and small-molecule therapies associated with infection risk in PsA
MDedge Rheumatology
Early efficacy with guselkumab predicts lower radiographic progression in PsA
MDedge Rheumatology